Bähr O - Search Results

1

ERGO: a pilot study of ketogenic diet in recurrent glioblastoma.

Rieger J, Bähr O, Maurer GD, Hattingen E, Franz K, Brucker D, Walenta S, Kämmerer U, Coy JF, Weller M, Steinbach JP. Rieger J, et al. Among authors: bahr o. Int J Oncol. 2014 Jun;44(6):1843-52. doi: 10.3892/ijo.2014.2382. Epub 2014 Apr 11. Int J Oncol. 2014. PMID: 24728273 Free PMC article. Clinical Trial.

2

Bevacizumab-induced diffusion-restricted lesions in malignant glioma patients.

Rieger J, Bähr O, Müller K, Franz K, Steinbach J, Hattingen E. Rieger J, et al. Among authors: bahr o. J Neurooncol. 2010 Aug;99(1):49-56. doi: 10.1007/s11060-009-0098-8. Epub 2009 Dec 25. J Neurooncol. 2010. PMID: 20035366

3

Differential utilization of ketone bodies by neurons and glioma cell lines: a rationale for ketogenic diet as experimental glioma therapy.

Maurer GD, Brucker DP, Bähr O, Harter PN, Hattingen E, Walenta S, Mueller-Klieser W, Steinbach JP, Rieger J. Maurer GD, et al. Among authors: bahr o. BMC Cancer. 2011 Jul 26;11:315. doi: 10.1186/1471-2407-11-315. BMC Cancer. 2011. PMID: 21791085 Free PMC article.

4

Bevacizumab-induced tumor calcifications as a surrogate marker of outcome in patients with glioblastoma.

Bähr O, Hattingen E, Rieger J, Steinbach JP. Bähr O, et al. Neuro Oncol. 2011 Sep;13(9):1020-9. doi: 10.1093/neuonc/nor099. Epub 2011 Jul 31. Neuro Oncol. 2011. PMID: 21807668 Free PMC article.

5

Quantitative T2 mapping of recurrent glioblastoma under bevacizumab improves monitoring for non-enhancing tumor progression and predicts overall survival.

Hattingen E, Jurcoane A, Daneshvar K, Pilatus U, Mittelbronn M, Steinbach JP, Bähr O. Hattingen E, et al. Among authors: bahr o. Neuro Oncol. 2013 Oct;15(10):1395-404. doi: 10.1093/neuonc/not105. Epub 2013 Aug 7. Neuro Oncol. 2013. PMID: 23925453 Free PMC article.

6

Sustained focal antitumor activity of bevacizumab in recurrent glioblastoma.

Bähr O, Harter PN, Weise LM, You SJ, Mittelbronn M, Ronellenfitsch MW, Rieger J, Steinbach JP, Hattingen E. Bähr O, et al. Neurology. 2014 Jul 15;83(3):227-34. doi: 10.1212/WNL.0000000000000594. Epub 2014 Jun 13. Neurology. 2014. PMID: 24928118

7

Prognostic factors in recurrent glioblastoma patients treated with bevacizumab.

Schaub C, Tichy J, Schäfer N, Franz K, Mack F, Mittelbronn M, Kebir S, Thiepold AL, Waha A, Filmann N, Banat M, Fimmers R, Steinbach JP, Herrlinger U, Rieger J, Glas M, Bähr O. Schaub C, et al. Among authors: bahr o. J Neurooncol. 2016 Aug;129(1):93-100. doi: 10.1007/s11060-016-2144-7. Epub 2016 May 18. J Neurooncol. 2016. PMID: 27193554

8

Bevacizumab for Patients with Recurrent Multifocal Glioblastomas.

Burger MC, Breuer S, Cieplik HC, Harter PN, Franz K, Bähr O, Steinbach JP. Burger MC, et al. Among authors: bahr o. Int J Mol Sci. 2017 Nov 20;18(11):2469. doi: 10.3390/ijms18112469. Int J Mol Sci. 2017. PMID: 29156610 Free PMC article.

9

Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide.

Glas M, Happold C, Rieger J, Wiewrodt D, Bähr O, Steinbach JP, Wick W, Kortmann RD, Reifenberger G, Weller M, Herrlinger U. Glas M, et al. Among authors: bahr o. J Clin Oncol. 2009 Mar 10;27(8):1257-61. doi: 10.1200/JCO.2008.19.2195. Epub 2009 Feb 2. J Clin Oncol. 2009. PMID: 19188676 Free article.

10

Bevacizumab impairs oxidative energy metabolism and shows antitumoral effects in recurrent glioblastomas: a 31P/1H MRSI and quantitative magnetic resonance imaging study.

Hattingen E, Jurcoane A, Bähr O, Rieger J, Magerkurth J, Anti S, Steinbach JP, Pilatus U. Hattingen E, et al. Among authors: bahr o. Neuro Oncol. 2011 Dec;13(12):1349-63. doi: 10.1093/neuonc/nor132. Epub 2011 Sep 2. Neuro Oncol. 2011. PMID: 21890539 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

73 results

Search Page